The Next Competitive Advantage In Clinical Trials Is Execution Intelligence

By Abraham Gutman, Founder and CEO, AG Mednet

Right now, everyone is talking about AI making clinical trials faster. But there is a huge gap: even though we have fancy software to track data, we still don't really know why trials succeed or fail to run smoothly. Most of the "real work"—like making tough decisions or fixing mistakes—happens in emails and meetings, not in the systems AI can see. This is the "Execution Blind Spot." If your trial’s decision-making process is a mess, AI will just give you "helpful" suggestions that don't actually fit how things work in the real world. The bottleneck isn't the AI—it’s the disorganized way we manage trials. The winners in this industry won’t be the ones with the flashiest AI; they’ll be the ones who finally fixed their messy "under-the-hood" operations so the AI actually has something useful to do. Learn more about how AI serves as a catalyst for visibility and the competitive advantage that will go to whoever redesigns their operating environments to be AI-ready.